Canadian Journal of Gastroenterology (Jan 2007)

N-acetyltransferase 2 Slow Acetylator Genotype Associated with Adverse Effects of Sulfasalazine in the Treatment of Inflammatory Bowel Disease

  • Min Chen,
  • Bing Xia,
  • Bixiao Chen,
  • Qiusha Guo,
  • Jin Li,
  • Mei Ye,
  • Zhengguo Hu

DOI
https://doi.org/10.1155/2007/976804
Journal volume & issue
Vol. 21, no. 3
pp. 155 – 158

Abstract

Read online

AIM: N-acetyltransferase 2 (NAT2) is an important enzyme catalyzing N-acetylation of sulfasalazine (SASP). The aim of the present study was to investigate associations of the genotypes of NAT2 with inflammatory bowel disease (IBD), and with adverse effects of SASP, which is used as the first-line treatment of IBD.